Opinion|Videos|October 28, 2024
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC
Key Takeaways
- Multidisciplinary teams should integrate oncologists and urologists, emphasizing patient-centered care for high-risk non–muscle-invasive bladder cancer.
- Global preparation involves understanding diverse market needs and ensuring access to resources and education.
Panelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What does an ideal multidisciplinary team look like in BCG-naive, high-risk non–muscle-invasive bladder cancer? How can the team (oncologists & urologists) prepare globally (in different markets) to set up patients for the most success?
- What education or resources are needed prior to the launch of these products or prior to this evolving landscape to prepare for the launches?
- What adverse events need attention and education as part of the prelaunch preparation?
- Closing thoughts from each of the panelists.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD
4
Microbial dysbiosis may predict response to CBM588 in mRCC
5